Caliper Life Sciences, IntegenX enter license agreement for microfluidics patent portfolio

IntegenX Inc. (a privately held corporation) and Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced a license agreement providing IntegenX access to Caliper's microfluidics patent portfolio. IntegenX will leverage its proprietary MOVe™ microvalve technology and Caliper's microfluidic intellectual patent estate to accelerate commercialization of its Apollo 200 RapidHIT™ DNA Profiling System for human identification.

The Apollo 200 System automates the process of producing standardized DNA profiles from cheek swabs and other suitable human tissue samples. DNA profiles produced by the Apollo 200 System can be used to match collected samples with existing DNA records in domestic and international databases, or to expand those databases. Numerous local, state, national and international law enforcement and security agencies use DNA-based human identification to inform decisions regarding the arrest or release of suspected terrorists and other criminals, to protect national borders, and to analyze crime scene evidence. The Apollo 200 System reduces the time required to produce a standard human identification DNA profile from approximately 15 hours to less than two hours.

"The license agreement with Caliper supports our 'sample-to-answer' strategy and enables us to build upon IntegenX's core strengths in product development and integration," said Stevan Jovanovich, PhD, President and CEO of IntegenX. "Microfluidics is a key enabling technology behind the high degree of automation and unprecedented analytical speed we've achieved."

"The use of microfluidics for rapid DNA identification is an exciting market development," said Kevin Hrusovsky, President and CEO of Caliper. "We continue to leverage Caliper's microfluidics portfolio, through licensing collaborations, to extend our market reach and create revenue opportunities beyond our direct product offerings."